ACROBiosystems

ACROBiosystems

Biotechnology Research

Newark, Delaware 28,050 followers

Where Proteins and Innovation Advance Biomedicine

About us

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
Newark, Delaware
Type
Public Company
Founded
2010
Specialties
Proprietary HEK293 expression platform, In-house developed enzymatic and chemical biotin labeling technique, covid-19 antigens and antibodies, CAR-T, Reagents for COVID-19 vaccine development and evaluation, SARS-CoV-2 Related Kit Products, Targets for Antibody-Drug Conjugates, Hot target for bispecific antibody, CD3, Bispecific Antibody, Sars-cov-2 mutants, ADCs, Sars-cov-2 kits, Targets for CAR-T Cell Therapy, Multi-pass Transmembrane Proteins and Technology Platforms, Immune Checkpoint, Cytokine, BsAb targets, Fc Receptors, MABSOL Biotinylated Protein, Enzymes, Anti-idiotypic Antibodies, Cell Gene Therapy, and GMP grade Cytokines

Locations

Employees at ACROBiosystems

Updates

Affiliated pages

Similar pages

Browse jobs

Funding

ACROBiosystems 3 total rounds

Last Round

Series B
See more info on crunchbase